Third Quarter 2025 Financial Results: Total revenue for the quarter ended September 30, 2025 was $134.2 million, up 12% from $119.8 million in the same period of 2024. This growth and operational ...
The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
Details of the novel pharmacokinetic assay for measuring SAB-142.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback